Poseida Therapeutics Inc (NASDAQ: PSTX) kicked off on Tuesday, up 0.11% from the previous trading day, before settling in for the closing price of $9.44. Over the past 52 weeks, PSTX has traded in a range of $1.87-$9.48.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 53.46% over the last five years. While this was happening, its average annual earnings per share was recorded 48.36%. With a float of $67.28 million, this company’s outstanding shares have now reached $97.41 million.
The firm has a total of 330 workers. Let’s measure their productivity. In terms of profitability, gross margin is 95.42%, operating margin of -41.43%, and the pretax margin is -40.25%.
Poseida Therapeutics Inc (PSTX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Poseida Therapeutics Inc is 30.97%, while institutional ownership is 55.76%. The most recent insider transaction that took place on Nov 26 ’24, was worth 278,100. In this transaction Executive Chairman of this company sold 30,000 shares at a rate of $9.27, taking the stock ownership to the 651,291 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Director proposed sale 120,000 for $2.86, making the entire transaction worth $343,200.
Poseida Therapeutics Inc (PSTX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 48.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.70% during the next five years compared to -12.83% drop over the previous five years of trading.
Poseida Therapeutics Inc (NASDAQ: PSTX) Trading Performance Indicators
Take a look at Poseida Therapeutics Inc’s (PSTX) current performance indicators. Last quarter, stock had a quick ratio of 3.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.11.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.63, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.69 in one year’s time.
Technical Analysis of Poseida Therapeutics Inc (PSTX)
Analysing the last 5-days average volume posted by the [Poseida Therapeutics Inc, PSTX], we can find that recorded value of 1.17 million was better than the volume posted last year of 0.73 million. As of the previous 9 days, the stock’s Stochastic %D was 86.84%. Additionally, its Average True Range was 0.41.
During the past 100 days, Poseida Therapeutics Inc’s (PSTX) raw stochastic average was set at 99.30%, which indicates a significant increase from 99.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 481.66% in the past 14 days, which was higher than the 202.17% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.02, while its 200-day Moving Average is $3.25. Now, the first resistance to watch is $9.50. This is followed by the second major resistance level at $9.55. The third major resistance level sits at $9.60. If the price goes on to break the first support level at $9.40, it is likely to go to the next support level at $9.35. Now, if the price goes above the second support level, the third support stands at $9.30.
Poseida Therapeutics Inc (NASDAQ: PSTX) Key Stats
The company with the Market Capitalisation of 921.04 million has total of 97,465K Shares Outstanding. Its annual sales at the moment are 64,700 K in contrast with the sum of -123,430 K annual income. Company’s last quarter sales were recorded 71,750 K and last quarter income was 20,240 K.
